13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13G Filed 2026-08-14 Event — SEC 0001104659-26-097425 →

ADAR1 Capital Management, LLC → Rein Therapeutics, Inc. RNTX

Stake: — Shares: — Class: Common Stock, $0.001 par value per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
9 13D/G filings on this issuer
8 other filings besides this one
Filer Track Record
14 filings by this filer
13 other filings in the data moat
Short Interest · settle 2026-09-30
DTC 2.35
651,179 shares short · -2.9% vs prior

Other 13D/G Filings on Rein Therapeutics, Inc.

FiledFormFilerStakeShares
2021-01-08 SC Satter Muneer A — — view →
2020-06-09 SC Satter Muneer A — — view →
2020-04-16 SC Novartis Bioventures Ltd — — view →
2020-04-13 SC Novartis Bioventures Ltd — — view →
2020-03-18 SC Novartis Bioventures Ltd — — view →
2019-08-13 SC Lilly Ventures Fund I LLC — — view →
2019-04-03 SC Novartis Bioventures Ltd — — view →
2019-03-18 SC Novartis Bioventures Ltd — — view →

Other Filings by ADAR1 Capital Management, LLC

FiledFormIssuerStakeShares
2026-09-08 SCHEDULE 13G Tenax Therapeutics, Inc. — — view →
2026-08-14 SCHEDULE 13G Cyclerion Therapeutics, Inc. — — view →
2026-08-14 SCHEDULE 13G Yarrow Bioscience, Inc. — — view →
2026-08-14 SCHEDULE 13G NextCure, Inc. — — view →
2026-08-14 SCHEDULE 13G Editas Medicine, Inc. — — view →
2026-08-14 SCHEDULE 13G JATT II Acquisition Corp. — — view →
2026-08-14 SCHEDULE 13G Amanat Acquisition Corp. — — view →
2026-08-14 SCHEDULE 13G Boundless Bio, Inc. — — view →
2026-08-14 SCHEDULE 13G Pliant Therapeutics, Inc. — — view →
2026-08-14 SCHEDULE 13G Research Alliance Corporation III — — view →
2026-06-05 SCHEDULE 13G InMed Pharmaceuticals, Inc. INM — — view →
2026-06-05 SCHEDULE 13G Rallybio Corporation RLYB — — view →
2025-04-28 SCHEDULE Keros Therapeutics, Inc. KROS 13.29% 5,390,964 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →